PS
CSTL icon

Principal Securities’s Castle Biosciences CSTL Stock Holding History

Principal Securities’s Portfolio CSTL Stock Details CSTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-76
Closed -$1.73K – 1795
2025
Q3 		$1.73K Hold
76
– – ﹤0.01% 3268
2025
Q2 		$1.55K Sell
76
-14
-16% -$259 ﹤0.01% 3223
2025
Q1 		$2.4K Hold
90
– – ﹤0.01% 2995
2024
Q4 		$2.4K Hold
90
– – ﹤0.01% 2990
2024
Q3 		$2.57K Buy
90
+36
+67% +$916 ﹤0.01% 2877
2024
Q2 		$1.18K Hold
54
– – ﹤0.01% 3032
2024
Q1 		$1.2K Sell
54
-129
-70% -$2.81K ﹤0.01% 3001
2023
Q4 		$3.95K Buy
+183
New +$3.22K ﹤0.01% 2616

Other funds holding CSTL

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return
PCM
Portolan Capital Management Boston, Massachusetts $1.88B AUM 115.74% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
SPPAM
Summit Partners Public Asset Management Boston, Massachusetts $3.72B AUM 162.29% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return

Principal Securities's CSTL Position: Q4 2025 in Review

Principal Securities sold out of Castle Biosciences (CSTL) in Q4 2025, closing a stake of 76 shares — an estimated $1.73K sold.

Principal Securities first reported a position in CSTL in Q4 2023 and held it in 8 quarters. The position peaked at $3.95K in Q4 2023. 194 funds tracked by Wall St. Rank hold CSTL as of Q4 2025.

  • Principal Securities reported no remaining Castle Biosciences position as of Q4 2025 after selling out during the quarter.
  • Principal Securities sold 76 Castle Biosciences shares in Q4 2025, an estimated $1.73K.
  • Principal Securities first reported a position in Castle Biosciences in Q4 2023 and held it in 8 quarters.
  • Principal Securities's Castle Biosciences position peaked at $3.95K in Q4 2023.
  • 194 funds tracked by Wall St. Rank held Castle Biosciences as of Q4 2025.

Based on Principal Securities's 13F filing for Q4 2025, filed 12 Feb 2026.